More than 300 employees with 20 or more years of service will be honored by the university during a reception 2 p.m. March 21 in the Hill Student Center; S. Robert Hernandez DrPH, will be honored for 50 years of service to UAB.

We are recruiting healthy men & women who are between 55-75 years of age AND have hypertension for the DECLARE Study.

The purpose of this research study is to examine the effects of 10 weeks of exercise on the brain. DEcreasing Cognitive Loss and Vascular Rarefaction with Exercise (DECLARE) is focused on the elucidation of exercise effects on brain health and the way by which exercise mitigates age-related growth factor deficiencies, hypertension and cognitive decline.

To participate in this research, you must:
– have high blood pressure
– be between 55-75 years of age
– be healthy (Ok to be on medication)
– not currently exercising

Please contact us at 205-996-5592 or use the following link to complete the 5 minute screening questionnaire: https://uab.co1.qualtrics.com/jfe/form/SV_6FigP3lOJYdvl9c

This past year, more than 4,700 employees activated their My Health Rewards account, and more than 3,600 logged enough healthy behaviors to receive a payout of $50 or more. Activate your account and explore new ways to earn cash rewards.

One Breath Matters.

Are you or someone you care about age 25-35 and interested in lung health? Join the landmark Lung Health Cohort Research Study to improve the health of future generations.

The pioneering NIH-funded study will follow 4,000 young, healthy adults to paint a clearer picture of lung health and the factors involved in predicting and preventing lung disease.

To learn more, visit: Lung.org/lung-study 

The University of Alabama at Birmingham (UAB), in collaboration with Novo Nordisk, is conducting a 3-year research study to see if CagriSema, an investigational weekly medicine being studied for the treatment of obesity is also safe for the heart and blood vessels.

We are doing this study to see if CagriSema (Cagrilintide/semaglutide), a new medicine intended for the treatment of obesity, is safe for use in people living with obesity and cardiovascular disease. The study will also include some people with type 2 diabetes and/or chronic kidney disease.

You may qualify to participate if::

• You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral
• arterial disease)
• You are 55 years of age or older
• You are living with obesity (BMI ≥ 30 kg/m2 )
• You can have type 2 diabetes and/or chronic kidney disease
• You are able to attend regular clinic visits and receive phone calls over
• a period of 3 years

Want to know more about the REDEFINE 3 study?
Call the study team at (205) 996-4015 or via email ccnrn@uab.edu

Tatyana Gavrikova, Sherry Polhill and Aparna Tamhane are the fourth-quarter 2022 honorees of the UAB Shared Values in Action Program, which honors those whose work exemplifies and embodies Forging the Future's shared values. Nominations for first-quarter 2023 honorees are open through Feb. 28.

If you’re being treated for MDD and your current antidepressant medication(s) is not working, the SAVITRI Study might interest you. The SAVITRI Study is researching a potential MDD therapy to improve symptoms of depression, and you may be able to participate. This research study is now enrolling adults diagnosed with MDD. Those who qualify will receive the investigational medication (or placebo), study-specific medical exams, and study-specific laboratory tests at no cost. Participants in the SAVITRI Study must: be 18 to 65 years of age; have a clinical diagnosis of MDD; be currently on antidepressant medication(s); have had inadequate response to up to 5 oral antidepressant medications; and fulfill other eligibility criteria. For more information, please call (205) 996-5987 or email lalexander@uabmc.edu. Please mention SAVITRI in your message.

Do you have a loved one with agitation associated with Alzheimer’s dementia? Is their agitation becoming overwhelming? Examples of some easily identifiable agitated behaviors are: restlessness, screaming, shouting, throwing things, resistiveness, constant unwarranted requests for attention or help, pacing/aimless wandering, kicking, hitting others or self, pushing people, hurting self or others, tearing things or destroying property. In this study, researchers want to find out if an investigational drug called AVP-786 is safe and effective (useful) in managing agitation in adults with Alzheimer’s dementia, when compared to a placebo. If you are a caregiver for a person with Alzheimer’s disease, please call (205) 996-5987 or email lalexander@uabmc.edu for more information.

The RECOVER study was designed in partnership with many of the nation’s top experts in treatment-resistant depression, and approved by Medicare, to provide additional evidence of the benefit of VNS Therapy. If the results confirm previous studies, Medicare and other insurers may start to cover it.

People who participate in RECOVER will receive VNS Therapy and all study-related care at no cost to them.

To join the RECOVER study, you must be 18 years or
older and:

1. Currently depressed
2. Have depression, or bipolar depression, that has lasted for at least two years or recurred several times
3. Have tried at least four types of antidepressant treatments and not found them helpful
4. Have Medicare Insurance

Employees can learn about compliance with the Americans with Disabilities and Rehabilitation acts, explore best practices for engaging with students with disabilities, and access key resources during a new online training from UAB Disability Support Services.